Name:
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy.
Description:
Povetacicept in adult patients with pMN. Povetacicept is a dual BAFF/APRIL inhibitor administered by monthly subcutaneous injection. Povetacicept offers potential first-in-class therapy for patients with pMN.
Stage:
Set-up
Principal Investigator:
Professor Peter Conlon
Sponsor:
Vertex
Network Partners
